Trial Profile
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Calcium; Vitamin D
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- 01 Mar 2021 Results at 36 months, published in the Journal of Bone and Mineral Metabolism.
- 10 Sep 2018 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology